Evidence map›Paper›PMID 40296096›Full record

ArticleHarm reduction journal2025

Barriers and facilitators to safer supply pilot program implementation in Canada: a qualitative assessment of service provider perspectives.

Frishta Nafeh, Lucas Martignetti, Carol Strike, Gillian Kolla, Matthew Bonn, Caroline Brunelle, Jade Boyd, Elaine Hyshka, Cassidy Morris, Jolene Eeuwes and 5 more

Abstract read
In one paragraph

Article in Harm reduction journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Frishta NafehCentre On Drug Policy Evaluation, MAP Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, ON, Canada.
Lucas MartignettiCentre On Drug Policy Evaluation, MAP Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, ON, Canada.
Carol StrikeDalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
Gillian KollaFaculty of Medicine, Memorial University, St. John's, NL, Canada.
Matthew BonnCanadian AIDS Society, Ottawa, ON, Canada.
Caroline BrunelleDepartment of Psychology, University of New Brunswick, Fredericton, NB, Canada.
Jade BoydDepartment of Medicine, Division of Social Medicine, University of British Columbia, Vancouver, BC, Canada.
Elaine HyshkaSchool of Public Health, University of Alberta, Edmonton, AB, Canada.
Cassidy MorrisLondon InterCommunity Health Centre, London, ON, Canada.
Jolene EeuwesCentre On Drug Policy Evaluation, MAP Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, ON, Canada.
Heather HobbsAVI Health and Community Services, Victoria, BC, Canada.
Elizabeth HaywoodIsland Health Authority, Victoria, BC, Canada.
Bernadette PaulyCanadian Institute for Substance Use Research, University of Victoria, Victoria, BC, Canada.
Dan WerbCentre On Drug Policy Evaluation, MAP Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, ON, Canada.
Mohammad KaramouzianCentre On Drug Policy Evaluation, MAP Centre for Urban Health Solutions, St. Michael's Hospital, Toronto, ON, Canada. mohammad.karamouzian@unityhealth.to.

Funding

CIHR EV1-174804
6 · The paper itself

Abstract

backgroundIn response to the ongoing drug toxicity crisis, driven by fentanyl and its analogues in the unregulated drug supply, Canada has funded several safer supply programs, which provide pharmaceutical-grade medications to reduce the reliance on toxic unregulated drug supply for people who use drugs. In this study, we examined barriers and facilitators that influenced the implementation of integrated safer supply pilot programs (ISSPP) across Canada.

methodsBetween March 2022 and May 2023, we conducted a qualitative study using semi-structured interviews with key informants from ten ISSPP located in three provinces across Canada. Data analysis and interpretation of findings were guided by the Consolidated Framework for Implementation Research (CFIR). Thematic analysis was used to code transcripts and identify themes.

resultsISSPP varied greatly in the degree of ancillary and wraparound services provided. Additionally, differences existed across the ten programs in terms of eligibility criteria for enrolling clients and the availability of medication options. We found twelve constructs and three sub-constructs across four domains of CFIR that influenced the implementation of ISSPP. Implementation facilitators included low-barrier and client-centered delivery model, ongoing needs assessment through program monitoring and evaluation, integration of wraparound care, partnership with local services to coordinate client care, community buy-in, clinical protocols and standardized practices, and multidisciplinary care teams with motivated staff. Major barriers to ISSPP implementation were a volatile and toxic unregulated drug supply, complicated policy environments, unsustainable funding models, unsupportive regulatory environments, limited medication options, limited physical space, as well as staff shortage.

conclusionsDespite several internal implementation facilitators, ISSPP faced many external and policy-level implementation barriers. Future safer supply programs should be guided by evidence-based planning and implementation, drawing from successful experiences in harm reduction implementation. Implementation facilitators, in particular, evidence-based practice guidelines along with better monitoring of client outcomes can be leveraged to enhance quality of care, address client needs and preferences, and mitigate unintended harms.

Indexed as

Harm ReductionCanadaFentanylHumansPilot ProjectsQualitative ResearchFentanylDrug overdoseHarm reductionImplementation scienceSafer supplySubstance-related disorders

Identifiers

PMID40296096
PMCPMC12039088

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.